DOI QR코드

DOI QR Code

Hepatoprotecive Effects of Puerariae Flos Extract on Experimental Non-alcoholic Fatty Liver Disease Models

비알콜성 지방간 동물모델에서 갈화추출물의 간보호 효과

  • Hwang, Hyeong-Chil (Department of Oriental Pharmacy, College of Pharmacy, Wonkwang Oriental Medicines Research Institute, Wonkwang University) ;
  • Kong, Ryong (Department of Oriental Pharmacy, College of Pharmacy, Wonkwang Oriental Medicines Research Institute, Wonkwang University) ;
  • Kang, Ok-Hwa (Department of Oriental Pharmacy, College of Pharmacy, Wonkwang Oriental Medicines Research Institute, Wonkwang University) ;
  • Kwo, Dong-Yeul (Department of Oriental Pharmacy, College of Pharmacy, Wonkwang Oriental Medicines Research Institute, Wonkwang University)
  • 황형칠 (원광대학교 약학대학 한약학과, 원광한약연구) ;
  • 공룡 (원광대학교 약학대학 한약학과, 원광한약연구) ;
  • 강옥화 (원광대학교 약학대학 한약학과, 원광한약연구) ;
  • 권동렬 (원광대학교 약학대학 한약학과, 원광한약연구)
  • Received : 2018.07.25
  • Accepted : 2018.09.25
  • Published : 2018.09.30

Abstract

Objectives : The aim of this study is to investigate the preventive effect of Puerariae Flos ethanol extract (PE) on methionin and choline deficient (MCD)-diet-induced Nonalcoholic fatty liver disease (NAFLD) in C57BL/6J mice. Methods : In the in vivo experiments, C57BL/6J mice were divided into 4 groups; Normal group, Control group, MCD+PE 100 group, and MCD+PE 300 group. After 4 weeks, body weight, liver weight, biochemical parameters for liver function test, histological changes, reverse transcription polymerase chain reaction (RT-PCR), and Western blot were assessed. Results : Mice lost body weight with the MCD-diet and the MCD+PE 100 group and MCD+PE 300 groups lost less than the control group, though showed no statistical significance. Liver weights were decreased by the MCD diet, but MCD+PE 300 groups were increased significantly. In the liver function test, all the values were decreased with the MCD-diet, MCD+PE 100 group and MCD+PE 300 groups were increased significance. In histological findings of the livers, MCD-diet induced severe fatty accumulation in the livers, but this fatty change was reduced in the MCD+PE 100 group and MCD+PE 300 groups was inhibited respectively. In lipid accumulation factors (such as SREBP-1c, $C/EBP{\alpha}$, PPAR-${\gamma}$), MCD+PE 100 group and MCD+PE 300 groups showed inhibitory effect on liver lipogenesis by reducing associated gene expressions caused by MCD diet. Conclusions : We were able to know that Puerariae Flos ethanol extract (PE) shown hepatoprotective effects via a decrease on the hepatic lipogenesis factors in the experimental NAFLD Models.

Keywords

References

  1. Ko JS. Dermatology. Soomoonsa Press. 2000:73.
  2. Pavel S, Muskiet FA. Eumelanin (precursor) metabolites as markers for pigmented malignant melanoma, a preliminary report. Cancer Detect Prev. 1983;6:311-316.
  3. Prota, G. Recent advances in the chemistry of melanogenesis in mammals. J Invest Dermatol. 1980;75:122-127. https://doi.org/10.1111/1523-1747.ep12521344
  4. Parvez S, M Kang, HS Chung, C Cho, MC Hong, MK Shin, H Bae. Survey and mechanism of skin depigmenting and lightening agents. Phytother Res. 2006;20:921-934. https://doi.org/10.1002/ptr.1954
  5. Mayer A. M. Polyphenol oxidases in plants recent progress. Phytochemistry. 1987;26:11-20.
  6. Cabanes JS, Chazarra S, Garcia-Carmona F. Kojic acid, a cosmetic skin whitening agent, is a slow binding inhibitor of catecholase activity of tyrosinase. J Pharm Pharmacol. 1994;46:982-985. https://doi.org/10.1111/j.2042-7158.1994.tb03253.x
  7. Masashi N, Yasuteru K,Tooru S. Murine Models of Nonalcoholic Fatty Liver Disease and Steatohepatitis. 2012;2013:237870. doi: 10.1155/2013/237870.
  8. Andrew J Lickteig, Craig D Fisher, Lisa M Augustine, Nathan J. Cherrington. Genes of the Antioxidant Response Undergo Upregulation in a Rodent Model of Nonalcoholic Steatohepatitis. J Biochem Molecular Toxicology. 2007;219:216-220.
  9. Mu Y-ping, Ogawa T, Kawada N. Reversibility of fibrosis, inflammation, and endoplasmic reticulum stress in the liver of rats fed a methionine-cholinedeficient diet. Laboratory Investigation. J Technical Methods and Pathology. 2010;90:245-256.
  10. Heo J. Hwang sil donguibogam. Seoul: Geumjinpublishing. 1993;927.
  11. Kim CM, Sin MK, Lee KS, Ahn DK. Encyclopedia of oriental herbal medicine. Seoul:Jeongdam. 2004;2307.
  12. Kim TJ, Resources plants in Korea. Seoul:Seoul National University Publishing Council, 1986;232.
  13. Kubo M, Fujita K. A new irisolidone-7-Oglucoside and tectoridin from Pueraria species. Phytochemistry. 1973;12:25-47. https://doi.org/10.1016/S0031-9422(00)84620-8
  14. Kubo M, Sasaki M, Namba K, Naruto S, Nishimura H. Isolation of a new isoflavone from chinese Pueraria Flower. Chem Pharm Bull. 1975;23:2449-2451. https://doi.org/10.1248/cpb.23.2449
  15. Kurihara T, Kikuchi. Studies on the constituents of Flower (1): On the constituents of Flower of Pueraria thunbergiana Benth (2). Isolation of a new isoflavone glycoside. Yakugaku Zasshi. 1975;95: 1283-1285. https://doi.org/10.1248/yakushi1947.95.11_1283
  16. Park HJ, Park JH, Moon JO, Lee KT, Jung WT, Oh SR, Lee HK. Isoflavone glycosides from the Flower of Pueraria thunbergiana. Phytochemistry. 1999;51:147-151. https://doi.org/10.1016/S0031-9422(98)00729-8
  17. Hsu FL, Liu IM, Kuo DH, Chen WC, Su HC, Cheng JT. Antihyperglycemic effect of puerarin in sterptozotocin-induced diabetic rats. J Nature Products. 2003;66:788-792. https://doi.org/10.1021/np0203887
  18. Hwang YP, Choi CY, Chung YC, Jeon SS, Jeong HG. Protective effects of puerarin on carbon tetrachloride-induced hepatotoxicity. Arch Pharmacal Res. 2007;30:1309-1317. https://doi.org/10.1007/BF02980272
  19. Falchuk FR, Fiske SC, Haggitt RC, Federman M, Trey C. Pericentral hepatic fibrosis and intracellular hyalin in diabetes mellitus. Gastroenterology. 1980;78:535-541.
  20. Bacon BR. Genetic, metabolic, and infiltrative diseases affecting the liver. Harrison's principles of internal medicine. 17th ed. New York: McGraw-Hill. 2008;1980-1983
  21. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med. 2002;346:1221-1231. https://doi.org/10.1056/NEJMra011775
  22. Yun JW, Cho YK. Clinical impact of non-alcoholic fatty liver disease on other medical diseases. Korean J Intern Med. 2009;76(1):25-29.
  23. Brunt EM. Alcoholic and nonalcoholic steatohepatitis. Clin Liver Dis. 2002;6(2):399-420. https://doi.org/10.1016/S1089-3261(02)00002-8
  24. Leevy CM. Fatty liver. A study of 270 patients with biopsy proven fatty liver and review of the literature. Medicine. 1962;41:249-276. https://doi.org/10.1097/00005792-196209000-00003
  25. Wanless IR, Lentz JS. Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors. Hepatology. 1990;12: 1106-1110. https://doi.org/10.1002/hep.1840120505
  26. Eriksson S, Eriksson KF, Bondesson L. Nonalcoholic steatohepatitis in obesity: a reversible condition. Acta Med Scand. 1986;220:83-88.
  27. Kim MJ, Park CH, Kim DH, Park MH, Park KC, Hyun MK, Lee AK, Moon HR, Chung HY. Hepatoprotective Effects of MHY3200 on High-Fat, Diet-Induced, Non-Alcoholic Fatty Liver Disease in Rats. Molecules. 2018;23(8). doi: 10.3390/molecules23082057.
  28. Powell EE, Cooksley WG, Hanson R, Searle J, Halliday JW, Powell LW. The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years. Hepatology. 1990;11:74-80. https://doi.org/10.1002/hep.1840110114
  29. Lee RG. Nonalcoholic steatohepatitis: a study of 49 patients. Hum Path. 1989;20:594-598. https://doi.org/10.1016/0046-8177(89)90249-9
  30. Bacon BR, Faragvash MJ, Janny CG, Neuschwander-Tetri BA. Nonalcoholic steatohepatitis: an espanded clinical entity. Gastroenterology. 1994;107:1103-1109. https://doi.org/10.1016/0016-5085(94)90235-6
  31. Hsu FL, Liu IM, Kuo DH, Chen WC, Su HC, Cheng JT. Antihyperglycemic effect of puerarin in sterptozotocin-induced diabetic rats. J Nature Products. 2003;66:788-792. https://doi.org/10.1021/np0203887
  32. Hwang YP, Choi CY, Chung YC, Jeon SS, Jeong HG. Protective effects of puerarin on carbon tetrachloride-induced hepatotoxicity. Arch Pharmacal Res. 2007;30:1309-1317. https://doi.org/10.1007/BF02980272
  33. Gervois P, Torra IP, Fruchart JC, Staels B. Regulation of lipid and lipoprotein metabolism by PPAR activators. Clin Chem Lab Med. 2000;38:3-11.
  34. Foretz M, Guichard C, Ferre P, Foufelle F. Sterol regulatory element binding protein-1c is a major mediator of insulin action on the hepatic expression of glucokinase and lipogenesis-related genes. Proc Natl Acad Sci. 1999;96:12737-12742. https://doi.org/10.1073/pnas.96.22.12737
  35. Morrison CD, Huypens P, Stewart LK, Gettys TW. Implications of cross talk between leptin and insulin signaling during the development of dietinduced obesity. Biochim Biophys Acta. 2009;1792: 409-416. https://doi.org/10.1016/j.bbadis.2008.09.005
  36. Gomez-Lechon MJ, Donato MT, Martinez-Romero A, Jimenez N, Castell JV and O'Connor JE. A human hepatocellular in vitro model to investigate steatosis. Chem Biol Interact. 2007;165(2):106-116. https://doi.org/10.1016/j.cbi.2006.11.004